Granules India Ltd News

Nifty Pharma hits 52-wk high; Wockhardt up 15%, Laurus, Lupin at new peaks

The Nifty Pharma index was quoting higher for the fifth straight trading day, surging 3.8 per cent during the period, as against 0.37 per cent gain in Nifty 50.

Stocks to Watch today: Bharti Airtel, Adani Ports, PhysicsWallah, IndiGo

Stocks to Watch today, April 1, 2026: Shares of auto-related companies are expected to remain in focus today as they are set to report their March sales figures

Granules, Aurobindo Pharma among top stocks to buy today; check targets

Kunal Kamble, senior technical research analyst at Bonanza, has recommended buying shares of Aurobindo Pharma, Granules India, and Wheels India today

Stocks to buy today: Analyst suggests Centum Electronics, GPIL, Granules

Top stocks to buy today: Aakash Shah of Choice Broking recommends buying Centum Electronics, Godawari Power, Granules India shares today

Focus on "stock-specific" opportunities: Analyst; suggests 2 stocks to buy

Ajit Mishra of Religare Broking recommends buying Cummins India, Granules and selling Cipla futures; check all details here

Granules poised for stronger earnings cycle, says Elara; starts with 'Buy'

Over the past decade, Granules India, the brokerage said, has transitioned from a bulk API-led model to a US-focused formulations platform, with rising exposure to complex and differentiated products

Granules India share price rises over 4% as Q3 net profit increases 28%

The scrip gained as much as 4.32 per cent to ₹589.40, the highest level since January 19 on the National Stock Exchange (NSE)

Granules India gets USFDA tentative nod for generic ADHD treatment tablets

Granules India Ltd on Thursday said its arm Granules Pharmaceuticals, Inc has received tentative approval from the US health regulator for its generic amphetamine extended-release tablets indicated for treatment of attention deficit hyperactivity disorder, with eligibility of 180-day exclusivity. The tentative approval by the US Food and Drug Administration (USFDA) is for the abbreviated new drug application (ANDA) of Amphetamine extended-release tablets in strengths of 5 mg, 10 mg, 15 mg, and 20 mg, Granules India Ltd said in a regulatory filing. These are the generic equivalent of DYANAVEL XR, it added. "The Granules ANDA has been determined to be eligible for 180-day exclusivity by the FDA, reinforcing its growing capabilities in developing and commercialising complex and differentiated generic products for the US market," the company said. The product is indicated for the treatment of attention deficit hyperactivity disorder (ADHD) and has an estimated market size of USD 41 ...

Granules surges 18% in 1 month; why pharma stock hits 52-week high today?

Granules India plans to raise up to ₹1,762 crore from promoter, and non-promoter groups through a mix of convertible warrants and preferential issue of equity shares.